Project Grant R01CA310933
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $442K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $387,156 on August 10, 2026, under the Cancer Treatment Research program (CFDA 93.395) to advance TGF-beta-resistant CAR-NK cell therapy for acute myeloid leukemia. The work targets relapsed/refractory AML through a clinical trial using cord blood-derived CAR-NK cells engineered to express a truncated human CD27, CD28 costimulatory domain, CD3-zeta signaling domain, IL-15, and an inducible caspase-9 safety...
- The National Cancer Institute awarded The Johns Hopkins University $218,089 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and test engineered natural killer cell therapy targeting acute myeloid leukemia. The funded work develops chimeric cytokine receptor (CCR)-engineered NK cells designed to attack AML-associated surface antigens and overcome AML-mediated NK cell suppression. In Aim 1, the recipient will engineer NK cells to express dual interleukin...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The University of Texas MD Anderson Cancer Center a Project Grant of $1,847,485 under the Cancer Treatment Research program (CFDA 93.395) to advance next-generation CAR-NK (chimeric antigen receptor-engineered natural killer) cell therapies targeting CD5-positive T-cell malignancies. The award, effective September 19, 2025, with completion targeted for August 31, 2029, funds a clinical trial developing IC9/CAR5-28Z/IL-15...
- This federal Project Grant award of $566,998.00, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research targeting acute myeloid leukemia (AML) using a CD123-directed NK-cell engager and NK cell immune therapy, as well as harnessing the apoptotic machinery through BCL-2 inhibition. The project will be performed by the University of Texas MD Anderson Cancer Center in Houston, TX over a period from September 30, 2024 to...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $421,685 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to characterize clonal evolution and immune dysregulation in acute myeloid leukemia patients treated with venetoclax and azacitidine following allogeneic stem cell transplantation. The research addresses post-transplant AML relapse mechanisms by pursuing two primary aims: characterizing the mutational landscape at diagnosis,...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded Albert Einstein College of Medicine $431,970 under the Cancer Treatment Research program (CFDA 93.395) on April 1, 2026, to investigate combination approaches to acute myeloid leukemia targeting both CD123-directed NK cell engagers and BCL-2 inhibition through venetoclax. The research will employ dynamic BH3 profiling to probe mitochondrial priming mechanisms and test whether...
- This Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,127,579.00 to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System, to conduct a Phase 1b/2a clinical trial evaluating the anti-IL1RAP antibody nadunolimab in patients with myelodysplastic syndrome and acute myelogenous leukemia. The award commenced on September 30, 2023 and is scheduled for completion by September 29,...
- The National Cancer Institute awarded The University of Texas MD Anderson Cancer Center $579,658 on August 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to investigate immune dynamics in metastatic renal cell carcinoma to bone. The research illuminates the bone metastatic microenvironment in clear cell renal cell carcinoma, which accounts for approximately 80 percent of renal malignancies and occurs in approximately 40 percent of metastatic patients. MD...
- The National Cancer Institute, part of the Department of Health and Human Services, awarded $429,471 to the University of Texas at Austin on August 26, 2026, under the Cancer Treatment Research program (CFDA 93.395) to support research on therapeutic targeting of mitochondrial oxidative phosphorylation (OXPHOS) and lipid remodeling in relapsed acute myeloid leukemia (AML). The award funds investigation of metabolic vulnerabilities in venetoclax-resistant AML cells. The research explores...
- The National Cancer Institute awarded MD Anderson Cancer Center a $1.5 million Cooperative Agreement on July 23, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop clinical-grade combinatorial new approach methodologies (NAMs) assays for colorectal cancer treatment decisions. The recipient will validate three core methodologies—in vitro micro-organospheres (MOSs), in silico DL-Reflect, and VirtualCellTherapy—using clinical samples and patient outcomes across...